READ THE ORIGINAL ABSTRACT HERE.
- The malignancy outcome among patients with rheumatoid arthritis (RA) remains uncertain. It is also unclear whether these outcomes will be affected by various treatments. With widespread use of disease-modifying antirheumatic drugs (DMARDs) in patients with RA, especially combination conventional DMARDs and biologic DMARDs, the effect of combination therapy on malignancy needs to be addressed.
- Our results suggested no significant differences between Janus kinase inhibitors (JAKi) and methotrexate (MTX) combination versus MTX alone in all malignancies, non-melanomatous skin cancers (NMSC) and malignancies excluding NMSC. The overall side effect, including serious adverse events and deaths, was similar in the JAKi and MTX combination compared to MTX alone.
- There was no association between dose and malignancy rates in combination therapy groups versus MTX alone.
- We believe that our study well summarizes current available data and provides valuable information for physicians and patients regarding this pivotal topic.
- However, more data is needed from long-term studies, as there still exist latency periods from initiation of combination therapy to the onset of malignancy.
– Dr. Ni, study author